Novo Nordisk shocks investors: forecast lowered again
Another setback for Novo Nordisk. The Danish pharmaceutical company has lowered its forecast again. At the same time, the company has announced massive job cuts. Around 9,000 jobs are to be eliminated worldwide – equivalent to approximately 11.5 percent of the total workforce. Novo Nordisk shares lost almost five percent in early trading on Tradegate.
As the company announced on Wednesday morning, the company-wide transformation is expected to result in one-time restructuring costs of eight billion Danish kroner, including impairments. Restructuring costs of approximately nine billion Danish kroner will be incurred in the third quarter of 2025, offset by savings of approximately one billion Danish kroner in the fourth quarter. Accordingly, Novo Nordisk expects a one-time negative impact of approximately six percentage points on operating profit growth at constant exchange rates for the full year 2025 compared to the forecast published just a few weeks ago. The company now expects adjusted operating profit to grow between 4 and 10 percent at constant exchange rates. Previously, it had expected an increase of 10 to 16 percent.
Mike Doustdar, CEO of Novo Nordisk, commented: "As a global leader in obesity and diabetes, Novo Nordisk delivers life-changing products to patients around the world. But our markets are evolving, especially in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well. This means establishing a more performance-oriented culture, deploying our resources even more effectively, and prioritizing investments where they will have the greatest impact—in our leading therapeutic areas."
At the same time, Novo Nordsik announced job cuts of around 9,000 of its total 78,400 employees, including around 5,000 in Denmark.
Just a few weeks ago, Novo Nordisk lowered its profit growth forecast from 16 to 24 percent to 10 to 16 percent. Investors reacted with irritation. Novo Nordisk's share price fell by almost five percent in early trading on Tradegate. However, the forecast reduction at the time was under different management. Doustdar took over as CEO at the beginning of August. DER AKTIONÄR believes that the negative news at Novo Nordisk is now over. The obesity market continues to grow strongly, and the Danes remain well positioned here and have strong projects in the pipeline. However, investors will likely need to be patient. A stop loss of €38.00 secures the downside.
Note on conflicts of interest The board member and majority shareholder of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has directly and indirectly entered into positions in the following financial instruments or derivatives related to them mentioned in the publication, which could benefit from any price development resulting from the publication: Novo Nordisk.
It's every investor's dream: to find the next Amazon, Apple, Tesla, or Google before anyone else, to put it in your portfolio, not touch it for years, and then one day to own a ten-, twenty-, or even a hundred-fold increase. Or at least to find the companies whose shares outperform the overall market. The name of this art: "stock picking" – the selection of tomorrow's winners. Joel Tillinghast is one of the most successful stock pickers of all time. In this book, he shares his thoughts, methods, and strategies with the reader. He shows the mistakes the crowd makes, the niches to exploit, how to think, and much more. The bottom line is a textbook that will make its readers more successful investors.
deraktionaer.de
